Alexion’s Ultomiris Wins English Funding, Janssen’s Erleada Rejected

NICE Guidance Due On Astellas’s Xtandi For Prostate Cancer

 
• By Neena Brizmohun
  
Financial management
NICE's assessment showed that Ultomiris would be cost saving for the NHS • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from United Kingdom

More from Europe